Company Overview and News
The following slide deck was published by TravelSky Technology Ltd. ADR in conjunction with their 2017 Q4 earnings call.
Two subsidiary airlines of Chinese conglomerate HNA Group were briefly suspended by a state-owned accounting service after repeatedly missing payments, underscoring why concern continues to grow about the capital strain on one of the country’s biggest private overseas dealmakers.
There have been recent fears among economists and investors alike that China’s debt-fueled economy would contract as it transitions from old-school manufacturing to services, but the Asian giant has been far more resilient than most anticipated. Its gross domestic product for the second quarter rose 6.9 percent over the same period last year, beating expectations and putting the country on track to meet the International Monetary Fund’s 2017 growth forecast of 6.
This report contains terminology that may be unfamiliar to some readers. The Glossary gives definitions for frequently used terms.
LONDON, Aug. 1, 2017 /PRNewswire/ -- Passenger Service System (PSS) Market: Overview Passenger Service System (PSS) is a suite of solutions allowing efficient management of an airline front-end operation through managing passenger related activities. PSS solution is a communication system which provide passengers services such as customer care, loyalty, reservation, online booking, and check-in & check-out status in real-time.
Passenger Service System (PSS) is a suite of solutions allowing efficient management of an airline front-end operation through managing passenger related activities. PSS solution is a communication system which provide passengers services such as customer care, loyalty, reservation, online booking, and check-in & check-out status in real-time. The demand for passenger service system is expected to increase in the coming years owing to the growing demand of commercial aviation and increasing number of passengers.
Automation has already come in the form of software, but is expanding in the field of robotics.
SABR looks reasonably cheap after a steady decline over the past few months, trading at 8.5x 2017 Adjusted EBITDA guidance.
The company retains an inherent monopoly on the handling of flight transactions and information in China.
TORONTO - A Canadian investor group led by Stornoway Portfolio Management has an agreement to buy the main business of GuestLogix, a Toronto-based company that provides onboard payment systems for airlines and railways.
TORONTO, ONTARIO--(Marketwired - May 6, 2016) - GuestLogix Inc. ("GuestLogix" or the "Company") today announced that it has closed the previously announced sale of all of the shares that its wholly-owned subsidiary, GuestLogix Ireland Limited, owned in OpenJaw Technologies Inc. to an affiliate of TravelSky Technology Limited ("TravelSky") (the "OpenJaw Transaction"), for net proceeds of approximately US$38.
Analysts expect core business earnings at TravelSky Technology and China Travel International — China’s two leading travel companies by assets — to increase in 2016. That’s in line with management guidance.
Mooreland Continues as Active Advisor to the Travel and Hospitality Tech Market; Signature Transaction for Mooreland's Emerging China Cross-Border Practice
TORONTO, ONTARIO--(Marketwired - April 6, 2016) - - GuestLogix Inc. ("GuestLogix" or the "Company") today announced that it has entered into a definitive share purchase agreement in respect of the sale of all of the shares that its wholly-owned subsidiary, GuestLogix Ireland Limited, owns in OpenJaw Technologies Inc. to an affiliate of TravelSky Technology Limited (the "OpenJaw Transaction"). The OpenJaw Transaction resulted from the previously announced court-approved sale and investment solicitation process ("SISP") conducted under the Companies' Creditors Arrangement Act ("CCAA") under the supervision of PricewaterhouseCoopers Inc.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
23h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...